Literature DB >> 15187189

Pathogenesis of human papillomaviruses in differentiating epithelia.

Michelle S Longworth1, Laimonis A Laimins.   

Abstract

Human papillomaviruses (HPV) are the etiological agents of cervical and other anogenital malignancies. Over 100 different types of HPVs have been identified to date, and all target epithelial tissues for infection. One-third of HPV types specifically infect the genital tract, and a subset of these are the causative agents of anogenital cancers. Other HPV types that infect the genital tract induce benign hyperproliferative lesions or genital warts. The productive life cycle of HPVs is linked to epithelial differentiation. Papillomaviruses are thought to infect cells in the basal layer of stratified epithelia and establish their genomes as multicopy nuclear episomes. In these cells, viral DNA is replicated along with cellular chromosomes. Following cell division, one of the daughter cells migrates away from the basal layer and undergoes differentiation. In highly differentiated suprabasal cells, vegetative viral replication and late-gene expression are activated, resulting in the generation of progeny virions. Since virion production is restricted to differentiated cells, infected basal cells can persist for up to several decades or until the immune system clears the infection. The E6 and E7 genes encode viral oncoproteins that target Rb and p53, respectively. During the viral life cycle, these proteins facilitate stable maintenance of episomes and stimulate differentiated cells to reenter the S phase. The E1 and E2 proteins act as origin recognition factors as well as regulators of early viral transcription. The functions of the E5 and E1--E4 proteins are still largely unknown, but these proteins have been implicated in modulating late viral functions. The L1 and L2 proteins form icosahedral capsids for progeny virion generation. The characterization of the cellular targets of these viral proteins and the mechanisms regulating the differentiation-dependent viral life cycle remain active areas for the study of these important human pathogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187189      PMCID: PMC419925          DOI: 10.1128/MMBR.68.2.362-372.2004

Source DB:  PubMed          Journal:  Microbiol Mol Biol Rev        ISSN: 1092-2172            Impact factor:   11.056


  161 in total

1.  Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.

Authors:  Frauke Fehrmann; David J Klumpp; Laimonis A Laimins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network.

Authors:  J Doorbar; S Ely; J Sterling; C McLean; L Crawford
Journal:  Nature       Date:  1991-08-29       Impact factor: 49.962

3.  Induction of chromosome abnormalities in mouse and human epidermal keratinocytes by the human papillomavirus type 16 E7 oncogene.

Authors:  T Hashida; S Yasumoto
Journal:  J Gen Virol       Date:  1991-07       Impact factor: 3.891

4.  The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex.

Authors:  N Dostatni; P F Lambert; R Sousa; J Ham; P M Howley; M Yaniv
Journal:  Genes Dev       Date:  1991-09       Impact factor: 11.361

Review 5.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 6.  Papillomaviruses and cancer: from basic studies to clinical application.

Authors:  Harald zur Hausen
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

7.  Estimates of the world-wide prevalence of cancer for 25 sites in the adult population.

Authors:  Paola Pisani; Freddie Bray; D Maxwell Parkin
Journal:  Int J Cancer       Date:  2002-01-01       Impact factor: 7.396

Review 8.  Src in cancer: deregulation and consequences for cell behaviour.

Authors:  Margaret C Frame
Journal:  Biochim Biophys Acta       Date:  2002-06-21

9.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Identification of a G(2) arrest domain in the E1 wedge E4 protein of human papillomavirus type 16.

Authors:  Clare E Davy; Deborah J Jackson; Qian Wang; Kenneth Raj; Phillip J Masterson; Nicola F Fenner; Shirley Southern; Scott Cuthill; Jonathan B A Millar; John Doorbar
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more
  215 in total

Review 1.  Genomic instability and cancer: lessons learned from human papillomaviruses.

Authors:  Nina Korzeniewski; Nicole Spardy; Anette Duensing; Stefan Duensing
Journal:  Cancer Lett       Date:  2010-11-13       Impact factor: 8.679

2.  KSHV co-infection regulates HPV16+ cervical cancer cells pathogenesis in vitro and in vivo.

Authors:  Lu Dai; Jing Qiao; Luis Del Valle; Zhiqiang Qin
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

3.  The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation.

Authors:  Benyue Zhang; Wei Chen; Ann Roman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-28       Impact factor: 11.205

Review 4.  Nothing but skin and bone.

Authors:  F Patrick Ross; Angela M Christiano
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

5.  The E6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms.

Authors:  Andreas Müller-Schiffmann; Julia Beckmann; Gertrud Steger
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

7.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

8.  Retrospective analysis of HPV 16/18-related disease burden using archival clinical samples.

Authors:  Naureen Ehsan Ilahi; Shoaib Naiyar Hashmi; Sobia Anwar; Sheeba Murad
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-30       Impact factor: 4.553

9.  Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein.

Authors:  Ewa Krawczyk; John A Hanover; Richard Schlegel; Frank A Suprynowicz
Journal:  Biochem Biophys Res Commun       Date:  2008-05-01       Impact factor: 3.575

10.  Genetic analysis of the E2 transactivation domain dimerization interface from bovine papillomavirus type 1.

Authors:  David Gagnon; Hélène Sénéchal; Claudia M D'Abramo; Jennifer Alvarez; Alison A McBride; Jacques Archambault
Journal:  Virology       Date:  2013-03-11       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.